Cohen Lawrence B Abb Vie Inc. Transaction History

Cohen Lawrence B

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 23, 2023	BUY	$133.59 - $154.65 $183,018 - $211,870	1,370 New	1,370 $204,000
Q4 2022 Feb 08, 2023	BUY	$138.31 - $165.87 $304,143 - $364,748	2,199 New	2,199 $355,000
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $331,929 - $411,831	-2,515 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$107.43 - $135.93 $270,186 - $341,863	2,515 New	2,515 $341,000
Q3 2021 Oct 26, 2021	SELL	$106.4 - $120.78 $639,038 - $725,404	-6,006 Closed	0 $0
Q1 2021 Apr 26, 2021	SELL	$102.3 - $112.62 $1,534 - $1,689	-15 Reduced 0.25%	6,006 $650,000
Q4 2020 Feb 10, 2021	BUY	$80.49 - $108.67 $7,163 - $9,671	89 Added 1.5%	6,021 $645,000
Q1 2020 Apr 22, 2020	BUY	$64.5 - $97.79 $77,400 - $117,348	1,200 Added 25.36%	5,932 $452,000
Q3 2019 Nov 04, 2019	SELL	$62.98 - $75.72 $7,368 - $8,859	-117 Reduced 2.41%	4,732 $358,000
Q2 2019 Aug 01, 2019	BUY	$65.7 - $83.98 $318,579 - $407,219	4,849 New	4,849 $353,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Cohen Lawrence B, based on Form 13F filings with the SEC.

Stay updated on Cohen Lawrence B with notifications on news.